NCT02951702View on ClinicalTrials.gov

Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics

PHASE4CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

July 31, 2017

Conditions
Clostridium Difficile InfectionProphylaxisVancomycin
Interventions
DRUG

Vancomycin Oral

"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician"

All Listed Sponsors
lead

St. Luke's Hospital, Chesterfield, Missouri

OTHER

NCT02951702 - Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics | Biotech Hunter | Biotech Hunter